3-(2-Pyridyl)-5-(5-chloro-2-aminophenyl)-1,2,4-oxadiazole | 327056-44-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(2-Pyridyl)-5-(5-chloro-2-aminophenyl)-1,2,4-oxadiazole
• 英文别名: 4-chloro-2-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)aniline
• CAS: 327056-44-0
• 化学式: C₁₃H₉ClN₄O
• 分子量: 272.69
• InChiKey: VDRQQSBBJKJUPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• NEW USE
  申请人：AstraZeneca AB

  公开号：EP1896011A1

  公开（公告）日：2008-03-12
• New use
  申请人：Lehmann Anders

  公开号：US20070010553A1

  公开（公告）日：2007-01-11

  The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment or prevention of cough.
• Use
  申请人：Edwards Louise

  公开号：US20090054491A1

  公开（公告）日：2009-02-26

  The present invention relates to the use of compounds of formula II for the treatment or prevention of obesity.
• [EN] NOVEL TREATMENT OF GERD<br/>[FR] NOUVEAU TRAITEMENT DU REFLUX GASTROOESOPHAGIEN PATHOLOGIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2005060961A2

  公开（公告）日：2005-07-07

  The present invention relates to the use of a compound of formula (II) for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of compounds of formula (II) for the treatment of gastro-esophageal reflux disease.
• [EN] TREATMENT OF REFLUX-RELATED DISEASES<br/>[FR] TRAITEMENT DE MALADIES ASSOCIEES AUX REFLUX GASTRO-OESOPHAGIENS
  申请人：ASTRAZENECA AB

  公开号：WO2005060971A1

  公开（公告）日：2005-07-07

  The present invention relates to the use of certain compounds for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of certain compounds for the treatment of gastro-esophageal reflux disease, regurgitation, asthma, laryngitis, lung disease and for managing failure.